Evasión y resistencia
El cáncer frente a nuestras defensas
DOI:
https://doi.org/10.29105/bys9.17-228Keywords:
cancer, immune system, immune evasionAbstract
Cancer is a complex disease that can appear in any part of the body. Normally, the immune system, which is in charge of defending us, is responsible for detecting and eliminating abnormal cells, making sure that everything is in order. This process is called immunosurveillance. However, cancer can adapt and find ways to “hide” from the immune system. This is called cancer immunoediting, and it occurs in three stages: elimination, balance, and escape. In this article, we will explore what happens at each of these stages and how malignant cells manage to survive and advance.
Downloads
References
Ashraf, S., Nowsheen, S., Yang, X., Choi, B.K., Kwon, B.S. 2015. Cancer immune evasion: Mechanistic bases and therapeutic strategies. Seminars in Cancer Biology, 35(Suppl): S185–S198. https://doi.org/10.1016/j.semcancer.2015.03.004.
Dhatchinamoorthy, K., J.D. Colbert, K.L. Rock. 2021. Cancer immune evasion through loss of MHC class I antigen presentation. Frontiers in Immunology. 12:636568. https://doi.org/10.3389/fimmu.2021.636568
Dunn, G.P., L.J. Old, R.D. Schreiber. 2004. The immunobiology of cancer immunosurveillance and immunoediting. Immunity. 21(2):137–148. https://doi.org/10.1016/j.immuni.2004.07.017
Fessas, P., H. Lee, S. Ikemizu, T. Janowitz. 2017. A molecular and preclinical comparison of the PD-1–targeted T-cell checkpoint inhibitors nivolumab and pembrolizumab. Seminars in Oncology. 44(2):136–140. https://doi.org/10.1053/j.seminoncol.2017.06.002
Geoffrey-Cooper, M. 2000. The development and causes of cancer. Pp. [sin paginación en línea]. En: Cooper, G.M. (Ed.). The Cell: A Molecular Approach. 2ª ed. Sunderland, MA: Sinauer Associates. Disponible en: https://www.ncbi.nlm.nih.gov/books/NBK9963/
Guerra González, A., E. Silva, S. Montero, D.J. Rodríguez, R. Mansilla, J.M. Nieto-Villar. 2020. Metástasis: un hito para el conocimiento, un reto para la ciencia. Revista Cubana de Medicina. http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0034-75232020000100006&lng=es&tlng=es
Han, Y., D. Liu, L. Li. 2020. PD-1/PD-L1 pathway: current researches in cancer. PubMed. 10(3):727–742. https://pubmed.ncbi.nlm.nih.gov/32266087
Huang, J., F. Liu, C. Li, X. Liang, C. Li, Y. Liu, Z. Yi, L. Zhang, S. Fu, Y. Zeng. 2022. Role of CD47 in tumor immunity: a potential target for combination therapy. Scientific Reports. 12(1):13764. https://doi.org/10.1038/s41598-022-13764-3
Hui, L., Y. Chen. 2015. Tumor microenvironment: Sanctuary of the devil. Cancer Letters. 368(1):7–13. https://doi.org/10.1016/j.canlet.2015.07.039
INEGI. 2024. Estadísticas a propósito del día mundial contra el cáncer. En: https://www.inegi.org.mx (consultado el 01/02/2025).
Kamal, N., M.A. Ilowefah, A.R. Hilles, N.A. Anua, T. Awin, H.A. Alshwyeh, S.K. Aldosary, N.G.S. Jambocus, A.A. Alosaimi, A. Rahman, S. Mahmood, A. Mediani. 2022. Genesis and mechanism of some cancer types and an overview on the role of diet and nutrition in cancer prevention. Molecules. 27(6):1794. https://doi.org/10.3390/molecules27061794
Ling, S.P., L.C. Ming, J.S. Dhaliwal, M. Gupta, C. Ardianto, K.W. Goh, Z. Hussain, N. Shafqat. 2022. Role of immunotherapy in the treatment of cancer: A systematic review. Cancers. 14(21):5205. https://doi.org/10.3390/cancers14215205
Liu, C., M. Yang, D. Zhang, M. Chen, D. Zhu. 2022. Clinical cancer immunotherapy: Current progress and prospects. Frontiers in Immunology. 13:961805. https://doi.org/10.3389/fimmu.2022.961805
Liu, J., Z. Chen, Y. Li, W. Zhao, J. Wu, Z. Zhang. 2021. PD-1/PD-L1 checkpoint inhibitors in tumor immunotherapy. Frontiers in Pharmacology. 12:731798. https://doi.org/10.3389/fphar.2021.731798
López, M.M., A.F. Cardona. 2021. Historia del cáncer y el cáncer en la historia. Medicina. 42(4):528–562. https://doi.org/10.56050/01205498.1559
Mirlekar, B. 2022. Tumor promoting roles of IL-10, TGF-β, IL-4, and IL-35: Its implications in cancer immunotherapy. SAGE Open Medicine. 10:1–13. https://doi.org/10.1177/20503121211069012
Nicola, N.A., J.J. Babon. 2015. Leukemia inhibitory factor (LIF). Cytokine & Growth Factor Reviews. 26(5):533–544. https://doi.org/10.1016/j.cytogfr.2015.07.001
Park, J.H., J. Zhuang, J. Li, P.M. Hwang. 2016. p53 as guardian of the mitochondrial genome. FEBS Letters. 590(7):924–934. https://doi.org/10.1002/1873-3468.12061
Pascual-García, M., E. Bonfill-Teixidor, E. Planas-Rigol, C. Rubio-Perez, R. Iurlaro, A. Arias, I. Cuartas, A. Sala-Hojman, L. Escudero, F. Martínez-Ricarte, I. Huber-Ruano, P. Nuciforo, L. Pedrosa, C. Marques, I. Braña, E. Garralda, M. Vieito, M. Squatrito, E. Pineda, F. Graus, C. Espejo, J. Sahuquillo, J. Tabernero, J. Seoane. 2019. LIF regulates CXCL9 in tumor-associated macrophages and prevents CD8+ T cell tumor-infiltration impairing anti-PD1 therapy. Nature Communications. 10:2416. https://doi.org/10.1038/s41467-019-10369-9
Puleo, J., K. Polyak. 2021. A Darwinian perspective on tumor immune evasion. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 1877(1):188671. https://doi.org/10.1016/j.bbcan.2021.188671
Quezada, S.A., K.S. Peggs, T.R. Simpson, J.P. Allison. 2011. Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication. Immunological Reviews. 241(1):104–118. https://doi.org/10.1111/j.1600-065X.2011.01007.x
Reyes García, M.G., F. García Tamayo. 2013. Citocinas, inflamación y conducta. Vertientes. Revista Especializada en Ciencias de la Salud. 8:4–13. https://biblat.unam.mx/es/revista/vertientes-mexico-d-f/articulo/citocinas-inflamacion-y-conducta
Roy, P.S., B.J. Saikia. 2016. Cancer and cure: A critical analysis. Indian Journal of Cancer. 53(3):441–442. https://doi.org/10.4103/0019-509X.200658
Saxena, M., S.H. van der Burg, C.J.M. Melief, N. Bhardwaj. 2021. Therapeutic cancer vaccines. Nature Reviews Cancer. 21(6):360–378. https://doi.org/10.1038/s41568-021-00346-0
Sheikhlary, S., D.H. López, S. Moghimi, B. Sun. 2024. Recent Findings on Therapeutic Cancer Vaccines: An Updated Review. Biomolecules. 14(4):503. https://doi.org/10.3390/biom14040503
SuportaMed. 2023. Clasificación y tipos de cáncer. Clínica de Alta Especialidad. Disponible en: https://suportamed.com/cancer-clasificacion-tipos/ (consultado el 08/02/2025).
Tang, Q., Y. Chen, X. Li, S. Long, Y. Shi, Y. Yu, W. Wu, L. Han, S. Wang. 2022. The Role of PD-1/PD-L1 and the Application of Immune Checkpoint Inhibitors in Human Cancers. Frontiers in Immunology. 13:964442. https://doi.org/10.3389/fimmu.2022.964442
Vinay, D.S., E.P. Ryan, G. Pawelec, W.H. Talib, J. Stagg, E. Elkord, T. Lichtor, W.K. Decker, R.L. Whelan, H.M.C.S. Kumara, E. Signori, K. Honoki, A.G. Georgakilas, A. Amin, W.G. Helferich, C.S. Boosani, G. Guha, M.R. Ciriolo, S. Chen, S.I. Mohammed, A.S. Azmi, W.N. Keith, A. Bilsland, D. Bhakta, D. Halicka, H. Fujii, K. Aquilano, S.S.
Walsh, M.J., C.T. Stump, R. Kureshi, M. Dougan, D.M. Knipe, S.K. Dougan. 2023. IFNγ is a central node of cancer immune equilibrium. Cell Reports. 42(3):112219. https://doi.org/10.1016/j.celrep.2023.112219
World Health Organization (WHO). 2022. Cáncer. En: https://www.who.int/es/news-room/fact-sheets/detail/cancer (consultado el 08/02/2025).
Wu, D.-W., S.-P. Jia, S.-J. Xing, H.-L. Ma, X. Wang, Q.-Y. Tang, Z.-W. Li, Q. Wu, M. Bai, X.-Y. Zhang, X.-F. Fu, M.-M. Jia, Y. Tang, L. Chen, N. Li. 2024. Tumor Neoantigen Personalized Vaccines: Current Progress, Challenges, and Promising Future. Clinical and Experimental Medicine 24(1):229. https://doi.org/10.1007/s10238-024-01436-7
Ye, F., Y. Hu, W. Lu, C. Zhou, X. Xie. 2008. Expression of leukaemia inhibitory factor in epithelial ovarian carcinoma: correlation with clinical characteristics. Histopathology 53(2):224-228. https://doi.org/10.1111/j.1365-2559.2008.03068.x
Zheng, Y., Y.-C. Fang, J. Li. 2019. PD-L1 expression levels on tumor cells affect their immunosuppressive activity. Oncology Letters 18(5):5399-5407. https://doi.org/10.3892/ol.2019.10903
Downloads
Published
How to Cite
License
Copyright (c) 2026 Ximena Vázquez-Cadena, Diana Reséndez-Pérez, Vianey González-Villasana
This work is licensed under a Creative Commons Attribution 4.0 International License.
